IACRLRD 2019

Invited Speakers

ML01 Regulation of PCNA for Proper DNA Replication and Suppression of Genomic Instability Prof. Kyungjae Myung UNIST / Institute for Basic Science, Korea CV
ML02 Biological Heterogeneity of AML: Implications for Prognosis and Treatment Prof. Clara Bloomfield The Ohio State University, USA CV
ML03 Approaching Survival of the General Population: The Results of CML Study IV in the Global Context Prof. Rüdiger Hehlmann Heidelberg University, Germany CV
ML04 New Models of Human Leukemia Dr. Connie Eaves British Columbia Cancer Agency, Canada CV
ML05 Integrating CAR T-Cell Therapy into the Treatment of Lymphoma, Myeloma, and Leukemia: Strategies for Maximizing Patient Outcomes Prof. David G. Maloney Fred Hutchinson Cancer Research Center, USA CV
ML06 Leukemia Stem Cell and Bone Marrow Microenvironment Interactions Prof. Ravi Bhatia The University of Alabama at Birmingham, USA CV
ML07 Understanding Evolution and Outcomes in Myeloproliferative Neoplasms Dr. Jyoti Nangalia Wellcome Sanger Institute, UK CV

KS Infectious Origins of Some Leukemias & What To Do Dr. Robert C. Gallo University of Maryland, USA CV

SY01-1 HTLV-1/BLV Genomic Approaches to Understanding Adult T-cell Leukemia Dr. Anne Van den Broeke Jules Bordet Institute - ULB, Belgium CV
SY01-2 A Novel Epigenetic Drug against Adult T-cell Leukemia Prof. Toshiki Watanabe The University of Tokyo, Japan CV
SY01-3 Can We Cure Adult T Cell Leukemia/Lymphoma? Prof. Ali Bazarbachi American University of Beirut-Medical Center, Lebanon CV

SY02-1 DNA Methylation and Hydroxymethylation in Hematologic Differentiation and Transformation Prof. Myunggon Ko Ulsan National Institute of Science and Technology, Korea CV
SY02-2 Iron Toxicity in MDS Prof. Daniela Cilloni University of Torino, Italy CV
SY02-3 DDX41 Mutations in Myelodysplastic Syndrome Prof. Je-Hwan Lee University of Ulsan, Korea CV
SY02-4 Hypomethylation-based Combination Treatments: Where Epigenetics Meets Immunotherapy Prof. Michael Lübbert University of Freiburg Medical Center, Germany CV

LS01 Recent Advances of Treatment Strategy for Patient with CML: Insights from the UK SPIRIT2 Trial Prof. Richard Clark University of Liverpool, UK CV

SY03-1 The Rapidly Evolving Field of AML Prof. Gert Ossenkoppele Amsterdam University Medical Center, location VUMC, The Netherlands CV
SY03-2 Curative Treatment Options for Older Patients with AML Prof. Hervé Dombret Saint-Louis Institute for Research/ University of Paris, France CV
SY03-3 Development of A Novel FLT3 Inhibitor Prof. Hitoshi Kiyoi Nagoya University, Japan CV
SY03-4 Functional Genomic Approaches to Identifying New Therapeutic Strategies for AML Prof. Jeffrey Tyner Oregon Health & Science University, USA CV

SY04-1 Next Generation Sequencing for Chronic Myeloid Leukemia Prof. Susan Branford Centre for Cancer Biology, SA Pathology, Australia CV
SY04-2 New Horizon for CML Therapy: Treatment Discontinuation (TFR) Prof. Giuseppe Saglio University of Turin, Italy CV
SY04-3 Novel Agents for Chronic Myeloid Leukemia Prof. Michael Mauro Memorial Sloan Kettering Cancer Center, USA CV
SY04-4 Allogeneic Stem Cell Transplantation in CML Prof. Eduardo Olavarria Imperial College London, UK CV

SY05-1 Clinical and Biological Significance of RNA Editing Defect in Myeloma Prof. Wee Joo Chng National University Health System, Singapore CV
SY05-2 Current Approaches and Future Perspectives in the Treatment of Newly Diagnosed Myeloma Patients Prof. Roberto Mina University of Torino, Italy CV
SY05-3 Minimal Residual Disease: A Pitfall between Next-Generation Flow and Next-Generation Sequencing Analyses in Myeloma Prof. Dong Soon Lee Seoul National University, Korea CV

SY06-1 Analysis of CNS-ALL with Patient Derived Xenografts (PDX) Model Prof. Itaru Kato Kyoto University, Japan CV
SY06-2 Targeting Cell Adhesion-mediated Resistance in ALL Prof. Yong-Mi Kim University of Southern California, USA CV
SY06-3 Minimal Residual Disease and Targeted Therapy in Acute Lymphoblastic Leukemia Prof. Dieter Hoelzer Onkologikum Frankfurt, Germany CV
SY06-4 Ph+ ALL in Adults Evolving Place for TKIs, Chemotherapy, Immunotherapy and Transplantation Dr. Françoise Huguet University Institute of Cancer, France CV

LS02 Cutting Edge of Molecular Target Therapy and Therapeutic Strategies in CML Prof. Yosuke Minami National Cancer Center Hospital East, Japan CV

SY07-1 Understanding and Targeting the Stem Cell Origins of MDS and AML Prof. Ulrich Steidl Albert Einstein College of Medicine - Montefiore Medical Center, USA CV
SY07-2 Genetics and Mechanisms of Chemotherapy Resistance in ALL Prof. Adolfo Ferrando Columbia University, USA CV
SY07-3 Clonal Origin of Cancer Prof. Seishi Ogawa Kyoto University, Japan CV
SY07-4 Single-cell Sequencing for Understanding Tumor Heterogeneity and Evolution Prof. Semin Lee Ulsan National Institute of Science and Technology, Korea CV

SY08-1 Molecular Predictors and Prognosticators for the Clinical Management of Chronic Lymphocytic Leukemia Prof. Gianluca Gaidano University of Eastern Piedmont, Italy CV
SY08-2 CLL/SLL: from Genetics to the Clinic Prof. Wei Xu Jiangsu Province Hospital, China CV
SY08-3 Management of NK/T-cell Lymphoid Malignancy Prof. Seok Jin Kim Samsung Medical Center, Korea CV
SY08-4 Targeting Chronic Lymphocytic Leukemia in the Front Line Prof. Richard A. Larson The University of Chicago, USA CV

SY09-1 2020 Clinical, Laboratory, Molecular and Bone Marrow (CLMB) Classification and Treatment Options of Myeloproliferative Neoplasms Prof. Jan Jacques Michiels Goodheart Institute and Foundation, The Netherlands CV
SY09-2 Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis Prof. Ki-Seong Eom The Catholic University of Korea, Korea CV
SY09-3 Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Prof. Hideki Muramatsu Nagoya University, Japan CV

SY10-1 Study of Hematopoiesis Using Zebrafish Model System Dr. Yoonsung Lee UNIST / Institute for Basic Science, Korea CV
SY10-2 Nutrient Supply Specific to Chronic Myelogenous Leukemia Stem Cells Dr. Kazuhito Naka Hiroshima University, Japan CV
SY10-3 Overview of CAR-T Prof. Xiaojun Huang Peking University People's Hospital, China CV
SY10-4 AR T Cells in Hematologic Malignancies: What’s Next? Prof. Jae Park Memorial Sloan Kettering Cancer Center, USA CV